Navigation Links
Central Nervous System (CNS) Biomarkers Market: 2017 Forecast in New Research Report at ReportsnReports.com
Date:3/30/2013

Dallas, Texas (PRWEB) March 30, 2013

This report provides an overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response. Analysis of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017. Also evaluates technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages. The reports discusses CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others. The report provides patent analysis. And comprehensive company profiles of major players.

Report Scope
Biomarkers are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, indicate what treatment options may be most effective in an individual patient’s case and predict treatment response. They play a role both in new drug R&D and in predicting the outcome of treatment in the medical setting. They are important tools for understanding disease mechanism, developing more effective treatments and improving the quality of patient care.

The report examines the role of CNS biomarkers in early discovery, in drug development and for future diagnostics. The global CNS biomarker market (http://www.reportsnreports.com/reports/70523-central-nervous-system-cns-biomarkers-technologies-and-global-.html) is discussed, and forecasts are made for this segment of the industry for the five-year period from 2012 to 2017. The technological segments of the market (genomic
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
2. A molecule central to diabetes is uncovered
3. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
4. Florida-Based Team Gemini Signs Recycling Facility Agreement with Solid Waste Authority of Central Ohio
5. BioHealth Innovation, Inc. Forms Commercial Relevance Advisory Board to Help Advance Market-Relevant Innovations in Central Maryland
6. ‘Timely’ new undergrad program in photonics at University of Central Florida applauded by SPIE
7. Site Quality Management to Optimize Risk-Based and Centralized Monitoring, New Life Science Webinar Hosted by Xtalks
8. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
9. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
10. Dicom Systems and USARAD.com Announce Partnership and Introduce Beta Version of XMRI.com, New System by USARAD.com
11. Ellmans Pelleve™ Wrinkle Reduction System featured in "Sexy Eyes" segment on The Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... MONTREAL and YONGIN, South Korea ... with great pride that Green Cross Biotherapeutics Inc. (GCBT) ... will be located on the Montreal Technoparc,s Saint-Laurent Campus. ... green field investment projects in Canada ... construction of the first intravenous immunoglobulin (IVIG) and albumin ...
(Date:6/1/2015)... 2015  Novartis is highlighting data from an ... investigational chimeric antigen receptor (CAR) T cell therapy, ... specific types of hard-to-treat non-Hodgkin lymphoma. Findings from ... Pennsylvania,s Perelman School of Medicine (Penn) in adults ... lymphoma (DLBCL) and follicular lymphoma (FL) found an ...
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, ... of positive interim results from a poster presented ... open label randomised phase III trial of the ... in patients receiving cisplatin (Cis) monotherapy for standard ... the American Society of Clinical Oncology (ASCO) 2015 ...
(Date:6/1/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") ... at the ERA-EDTA Congress in London, England ... a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in ... Disease (CKD); a Post-hoc Analysis of Patients from the ... Dr. Kam Kalantar-Zadeh , Professor and Chief, Division ...
Breaking Biology Technology:Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4
... Aug. 4 OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), ... clinical trials announced today that the company has acquired the ... Ltd. The acquisition will be operated by OmniComm,s UK subsidiary, ... exceptional software is used to collect clinical trial data gathered ...
... molecule-sized pores are one step closer to replacing the ... of academic researchers is reporting. Writing this week ... membranes, ability to separate molecules in a mixture is ... processing (RTP). By heating the membranes from room temperature ...
... , , SAN FRANCISCO, Aug. ... positive drug sales/earnings and partnering and M&A deals. As a result, ... 6.5 percent, mirroring the Dow and Nasdaq, which closed the month ... for a July in years. , , Helping ...
Cached Biology Technology:OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd. 2OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd. 3Rapid heating prepares energy-saving zeolite for greater role in industrial separations 2Rapid heating prepares energy-saving zeolite for greater role in industrial separations 3Rapid heating prepares energy-saving zeolite for greater role in industrial separations 4Biotech Hot in July Driven by Positive Drug Data and Acquisitions 2Biotech Hot in July Driven by Positive Drug Data and Acquisitions 3Biotech Hot in July Driven by Positive Drug Data and Acquisitions 4Biotech Hot in July Driven by Positive Drug Data and Acquisitions 5
(Date:5/22/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... promotional pricing and making the Wocket generally available for $229 ... Head of Marketing said, "We,ve extended the opportunity to take ... May. To get your wocket at this special price, submit ... on June 1, you,ll receive a unique code that gives ...
(Date:5/20/2015)... 2015 Research ... the addition of the  "5-year Opportunity ... Market"  report to their offering.  ,     ... analyses trends in the iris recognition ... sectors, globally. Despite hardware pricing and ...
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
... at land-grant universities are a major source of ... industry. To prepare future employees for work in ... in nursery management and production, but availability of ... horticulture programs have contributed to a reduction in ...
... 2011 Dr. Daniel Von Hoff was presented this month ... in sequencing, or spelling out, the DNA of patients with ... advances the art of using the fully sequenced genomes of ... DNA, to help determine the best course of treatment. ...
... Mich. (March 17, 2011) In a ... so-called "orphan" nuclear receptor TR4, Van Andel Research Institute ... more direct role than was previously known in certain ... of the central nervous system. Scientists had previously ...
Cached Biology News:Integrating instructional multimedia in nursery management, production courses 2Dr. Daniel Von Hoff presented with top genomics award from Scripps 2Study indicates vitamin A plays key role in the human body 2
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
...
Biology Products: